###begin article-title 0
Alphabeta Hinders Nuclear Targeting of AICD and Fe65 in Primary Neuronal Cultures
###end article-title 0
###begin p 1
The intracellular domain of the Alzheimer's amyloid precursor protein (AICD) has been described as an important player in the transactivation of specific genes. It results from proteolytic processing of the Alzheimer's amyloid precursor protein (APP), as does the neurotoxic Abeta peptide. Although normally produced in cells, Abeta is typically considered to be a neurotoxic peptide, causing devastating effects. By exposing primary neuronal cultures to relatively low Abeta concentrations, this peptide was shown to affect APP processing. Our findings indicate that APP C-terminal fragments are increased with concomitant reduction in the expression levels of APP itself. AICD nuclear immunoreactivity detected under control conditions was dramatically reduced in response to Abeta exposure. Additionally, intracellular protein levels of Fe65 and GSK3 were also decreased in response to Abeta. APP nuclear signaling is altered by Abeta, affecting not only AICD production but also its nuclear translocation and complex formation with Fe65. In effect, Abeta can trigger a physiological negative feedback mechanism that modulates its own production.
###end p 1
###begin title 2
Keywords
###end title 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 233 237 230 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">1992</xref>
###xml 239 243 236 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">1993</xref>
###xml 252 256 249 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR32">1993</xref>
###xml 281 285 278 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">2004</xref>
###xml 341 345 334 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR34">1992</xref>
###xml 362 366 355 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">1998</xref>
###xml 384 388 377 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">2003</xref>
###xml 433 437 422 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">2000</xref>
###xml 453 457 442 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">2001</xref>
###xml 472 476 461 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">2002</xref>
###xml 489 493 478 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">2002</xref>
###xml 509 513 498 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">2005</xref>
###xml 730 734 706 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR35">1999</xref>
###xml 747 751 723 727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR39">2001</xref>
###xml 767 771 743 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">2007</xref>
###xml 1043 1047 1012 1016 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">2000</xref>
###xml 1066 1070 1035 1039 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">2009</xref>
###xml 1298 1302 1246 1250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">2001</xref>
###xml 1321 1325 1269 1273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">2001</xref>
###xml 1608 1612 1556 1560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR36">2004</xref>
###xml 1679 1683 1627 1631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">2001</xref>
###xml 1701 1705 1649 1653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">2001</xref>
###xml 1720 1724 1668 1672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR37">2003</xref>
###xml 1837 1840 1785 1788 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APP</italic>
###xml 1849 1853 1797 1801 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BACE</italic>
###xml 1855 1860 1803 1808 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tip60</italic>
###xml 1878 1882 1826 1830 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR36">2004</xref>
###xml 1885 1893 1833 1838 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSK3&#946;</italic>
###xml 1906 1910 1851 1855 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">2003</xref>
###xml 1931 1935 1876 1880 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">2005</xref>
###xml 1938 1942 1883 1887 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KAI1</italic>
###xml 1956 1960 1901 1905 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">2002</xref>
###xml 1967 1977 1912 1922 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Neprilysin</italic>
###xml 2003 2007 1948 1952 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">2005</xref>
Abeta was originally defined as a pathogenic peptide associated with Alzheimer's disease (AD), but it is now known to be produced during normal intracellular processing of the Alzheimer's amyloid precursor protein (APP; Haass et al. 1992, 1993; Selkoe 1993; da Cruz e Silva et al. 2004). Consecutive APP cleavage by alpha-secretase (Sisodia 1992; Buxbaum et al. 1998; Allinson et al. 2003) and the gamma-secretase complex (Li et al. 2000; Sastre et al. 2001; Esler et al. 2002; Lee et al. 2002; Capell et al. 2005) precludes Abeta production and produces a smaller fragment termed P3, whereas cleavage by beta-secretase and gamma-secretase results in the production of Abeta peptides, mainly in Golgi and endosomes (Vassar et al. 1999; Yan et al. 2001; Rebelo et al. 2007). The former non-amyloidogenic cleavage pathway also leads to the production of sAPPalpha, while the latter results in sAPPbeta production. Proteolytic sAPP products are typically secreted, although intracellular sAPP (isAPP) production has been detected (Carlson et al. 2000; Henriques et al. 2009). Resulting APP C-terminal fragments (CTFs), the products of alpha- and beta-secretase activities, may be cleaved by gamma-secretase at gamma- and epsilon-sites, giving rise to the APP intracellular domain (AICD; Sastre et al. 2001). Cao and Sudhof (2001) have shown that AICD exhibits transcriptional activity, enhanced by the formation of a transcriptional active complex comprising AICD, Fe65, and the histone acetylase Tip60. This trimeric complex was reported to localize to multiple spherical nuclear compartments (von Rotz et al. 2004). AICD and Fe65 localize together at the nucleus (Kimberly et al. 2001; Minopoli et al. 2001; Walsh et al. 2003), and nuclear AICD-containing complexes were reported to activate the transcription of several genes, including APP itself, BACE, Tip60 (von Rotz et al. 2004), GSK3beta (Kim et al. 2003; Ryan and Pimplikar 2005), KAI1 (Baek et al. 2002), and Neprilysin (Pardossi-Piquard et al. 2005). However, it is still unclear how the translocation of Fe65 and AICD from the cytoplasm and/or membrane into the nucleus is accomplished.
###end p 4
###begin p 5
###xml 122 126 119 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">1999</xref>
###xml 140 144 137 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">2001</xref>
###xml 160 164 157 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">1999</xref>
###xml 215 218 212 215 <sub xmlns:xlink="http://www.w3.org/1999/xlink">695</sub>
###xml 370 374 360 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR38">2007</xref>
APP/Fe65 interaction is also known to modulate APP metabolism, including sAPP secretion and Abeta production (Sabo et al. 1999; Ando et al. 2001). Sabo et al. (1999) reported that in MDCK cells stably expressing APP695, Fe65 increased APP translocation to the plasma membrane, which was accompanied by an increase in Abeta and sAPPalpha secretion. Recently, Xie et al. (2007) showed that Fe65 RNAi silencing leads to an increase in CTF levels and a decrease in Abeta levels, thus suggesting a role for Fe65 as a positive regulator of gamma-secretase activity.
###end p 5
###begin p 6
The present work focuses on the effect of exogenously added Abeta on APP metabolism in primary neuronal cultures and its effects on AICD/Fe65 nuclear signaling. The data obtained support the hypothesis that Abeta plays a role in APP processing and RIP signaling by altering APP intracellular proteolytic cleavage and by decreasing both APP and Fe65 intracellular and nuclear levels. The intracellular Abeta effects appear to include decreased AICD production, given the increase in CTFs production and decreased targeting and nuclear co-localization of AICD/Fe65.
###end p 6
###begin title 7
Materials and Methods
###end title 7
###begin title 8
Preparation and Maintenance of Primary Neuronal Cultures
###end title 8
###begin p 9
###xml 127 131 127 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">2007</xref>
###xml 363 364 357 358 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d</sc>
###xml 410 411 404 405 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 420 421 414 415 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 516 520 510 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">1993</xref>
###xml 741 742 733 734 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 0 3 <span type="species:ncbi:10116">Rat</span>
Rat cortical and hippocampal cultures were established from embryonic day 18 embryos as previously described (Henriques et al. 2007). After dissociation with trypsin (0.45 or 0.75 mg/ml for cortical or hippocampal cultures, respectively, for 5-10 min at 37degreesC) and deoxyribonuclease I (0.15 mg/ml) in Hank's balanced salt solution, cells were plated on poly-d-lysine-coated dishes at a density of 1.0 x 105 cells/cm2 in B27-supplemented Neurobasal medium (GIBCO), a serum-free medium combination (Brewer et al. 1993). The medium was supplemented with glutamine (0.5 mM), gentamicin (60 mug/ml), and with or without glutamate (25 muM) for hippocampal or cortical cultures, respectively. Cultures were maintained in an atmosphere of 5% CO2 at 37degreesC for 9 days before being used for experimental procedures.
###end p 9
###begin title 10
Incubation with Abeta Peptide
###end title 10
###begin p 11
###xml 5 10 2 7 <sub xmlns:xlink="http://www.w3.org/1999/xlink">25&#8211;35</sub>
###xml 203 208 196 201 <sub xmlns:xlink="http://www.w3.org/1999/xlink">25&#8211;35</sub>
###xml 312 317 302 307 <sub xmlns:xlink="http://www.w3.org/1999/xlink">25&#8211;35</sub>
###xml 93 96 <span type="species:ncbi:10116">Rat</span>
Abeta25-35 peptide (Sigma Aldrich) was dissolved in distilled water to prepare a 1 mM stock. Rat primary neuronal cultures were incubated for 24 h in Neurobasal medium free of B27 containing 20 muM Abeta25-35, with the medium being replaced during the last 3 h of incubation by fresh medium with or without Abeta25-35.
###end p 11
###begin title 12
Sample Collection and Immunoblotting
###end title 12
###begin p 13
###xml 187 191 184 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2004</xref>
###xml 544 549 <span type="species:ncbi:10090">mouse</span>
###xml 712 718 <span type="species:ncbi:9986">rabbit</span>
###xml 809 815 <span type="species:ncbi:9986">rabbit</span>
###xml 1117 1128 <span type="species:ncbi:3704">horseradish</span>
###xml 1156 1161 <span type="species:ncbi:10090">mouse</span>
###xml 1170 1176 <span type="species:ncbi:9986">rabbit</span>
Following exposure to Abeta, conditioned media and cells were collected in boiling 1% sodium dodecyl sulfate (SDS) and the lysates were homogenized as previously described (Amador et al. 2004). Protein determination was carried out using the BCA kit (Pierce). Samples normalized for protein content were separated on 7.5% or 5-20% gradient SDS polyacrylamide gels and then electrophoretically transferred onto nitrocellulose membranes for immunoblotting. Intracellular APP/isAPP and extracellular sAPP detection was carried out using the 22C11 mouse monoclonal antibody directed against the APP N terminus (Boehringer), while for holoAPP and endogenous C-terminal fragments, an APP C-terminal antibody was used (rabbit polyclonal anti-beta-APP C terminus, Zymed). Detection of total GSK3 was achieved using a rabbit polyclonal anti-glycogen synthase kinase 3 antibody (Chemicon). For Fe65 detection, the antibody clone 3H6 (Uspstate) was used, and tubulin detection was carried out using the monoclonal anti-beta-tubulin antibody (Zymed). Following incubation with the primary antibodies, immunodetection made use of horseradish peroxidase-conjugated anti-mouse or anti-rabbit IgGs secondary antibodies (Amersham Pharmacia), and for visualization, enhanced chemiluminescence detection (ECL) was employed (Amersham Pharmacia). The ECL Plus reagent was used for extracellular sAPP, CTFs, and Fe65 detection.
###end p 13
###begin title 14
Quantification
###end title 14
###begin p 15
###xml 416 417 414 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Quantity One densitometry software (Bio-Rad) was used to quantify band intensity and correlate it to protein levels. Data are expressed as mean +/- SEM of at least three independent experiments. Statistical analysis was carried out using one-way analysis of variance. When significantly different, the Dunnett test was applied to compare all groups to the control. The level of statistical significance accepted was P < 0.05.
###end p 15
###begin title 16
Northern Blot Analysis
###end title 16
###begin p 17
###xml 71 72 71 72 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 322 326 318 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">2009</xref>
###xml 366 368 362 364 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 408 409 404 405 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 497 500 493 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Age</italic>
###xml 502 505 498 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bam</italic>
###xml 547 550 543 546 <sub xmlns:xlink="http://www.w3.org/1999/xlink">751</sub>
###xml 580 582 572 574 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
Total RNA was isolated from control primary cortical cultures (3.0 x 106 cells) following Abeta treatment (TRI REAGENT, Sigma). Normalized total RNA aliquots (10 mug) were separated by formaldehyde gel electrophoresis and transferred to nitrocellulose membranes using standard laboratory protocols (da Cruz e Silva et al. 2009). The blot was then hybridized with a [32P]-labeled APP cDNA probe (25 ng, 1 x 106 cpm/ng) to evaluate APP expression levels. The APP probe used (756 bp) was obtained by AgeI/BamHI restriction enzyme digestion of the APP751 cDNA and labeled with [alpha-32P]dCTP (GE Healthcare) using the High Prime DNA labeling kit (Roche, Alfagene). Purification of the probe through NucTrap Probe purification columns (Stratagene, Alfagene) was performed prior to hybridization. APP hybridizing RNA was detected using Kodak Biomax XAR film (Sigma).
###end p 17
###begin title 18
Monitoring Nuclear Targeting of APP C-Terminal Proteolytic Products
###end title 18
###begin p 19
###xml 1409 1410 1409 1410 <italic xmlns:xlink="http://www.w3.org/1999/xlink">z</italic>
###xml 1417 1419 1417 1419 <italic xmlns:xlink="http://www.w3.org/1999/xlink">xy</italic>
###xml 184 190 <span type="species:ncbi:9913">bovine</span>
###xml 591 595 <span type="species:ncbi:9925">goat</span>
###xml 601 607 <span type="species:ncbi:9986">rabbit</span>
###xml 653 657 <span type="species:ncbi:9925">goat</span>
###xml 663 668 <span type="species:ncbi:10090">mouse</span>
For evaluating nuclear targeting of APP C-terminal proteolytic products and Fe65, cells were fixed with 4% paraformaldehyde, permeabilized with methanol for 2 min, and blocked with 3% bovine serum albumin in phosphate-buffered saline (PBS) for 1 h and further incubated with primary antibody (C-terminal APP antibody and Fe65 antibody) for 3 h. The antibody 4G8 (anti-Abeta 17-24 aa antibody, Chemicon) was used in co-localization studies with the APP C-terminal antibody to rule out nuclear CTFs and confirm the identity of AICD at the nucleus. After washing with PBS, Texas Red-conjugated goat anti-rabbit (Molecular Probes) or fluorescein-conjugated goat anti-mouse (Calbiochem) secondary antibodies were added for 2 h at room temperature. Coverslips were mounted on microscope glass slides using FluoroGuard (BioRad) as an antifading reagent or Vectashield (Vector Laboratories), an antifading reagent containing 4',6-diamidino-2-phenylindole (DAPI) for nucleic acid labeling. Nuclear targeting and co-localization studies of APP C-terminal fragments and Fe65 was carried out by immunofluorescence analysis. Acquisition of epifluorescence images made use of a LSM 510-Meta confocal microscope (Zeiss) and a 63x/1.4 oil immersion objective. The argon laser lines of 405 nm (DAPI), 488 nm (fluorescein), and a 561-nm DPSS laser (Texas Red) were used. Microphotographs were acquired in a sole section in the z-axis (xy mode) and represent a mean of 16 scans.
###end p 19
###begin title 20
Results and Discussion
###end title 20
###begin title 21
Abeta Affects APP Expression Levels
###end title 21
###begin p 22
###xml 102 105 96 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APP</italic>
###xml 224 228 218 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">1995</xref>
###xml 245 249 239 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">1997</xref>
###xml 266 270 260 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">2000</xref>
###xml 349 354 340 345 <sub xmlns:xlink="http://www.w3.org/1999/xlink">25&#8211;35</sub>
###xml 424 425 415 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 457 460 445 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APP</italic>
###xml 568 572 556 560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">1995</xref>
###xml 595 599 583 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">1998</xref>
###xml 681 684 666 669 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APP</italic>
###xml 854 855 836 837 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 1028 1029 1007 1008 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 1081 1084 1057 1060 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APP</italic>
###xml 1141 1149 1117 1125 <label xmlns:xlink="http://www.w3.org/1999/xlink">Figure&#160;1</label>
###xml 1165 1168 1138 1141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APP</italic>
###xml 1275 1280 1244 1249 <sub xmlns:xlink="http://www.w3.org/1999/xlink">25&#8211;35</sub>
###xml 1307 1328 1276 1297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Sec2" ref-type="sec">Materials and Methods</xref>
###xml 1331 1332 1300 1301 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1446 1447 1412 1413 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 1471 1475 1437 1441 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hAPP</italic>
###xml 1552 1553 1518 1519 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 1585 1586 1551 1552 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1596 1601 1562 1564 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A&#946;</italic>
###xml 1630 1631 1590 1591 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1149 1704 1125 1664 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="23">A&#946; decreases <italic>APP</italic> expression in primary neuronal cultures. Primary cortical neuronal cultures were treated with 20&#160;&#956;M A&#946;<sub>25&#8211;35</sub> for 24 h as described in &#8220;<xref rid="Sec2" ref-type="sec">Materials and Methods</xref>&#8221;. <bold>a</bold> Total mRNA was isolated and APP mRNA expression in primary cultures was monitored in response to A&#946; exposure. <bold>b</bold> Intracellular holoAPP (<italic>hAPP</italic>) protein detection was carried out using an antibody to the APP C terminus. <bold>c</bold> Tubulin was used as a control. <italic>C</italic> control, <italic>A&#946;</italic> A&#946; treatment for 24&#160;h. **<italic>P</italic>&#8201;&lt;&#8201;0.01, significantly different from control using Dunnett post hoc test</p>
###xml 1149 1704 1125 1664 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="23">A&#946; decreases <italic>APP</italic> expression in primary neuronal cultures. Primary cortical neuronal cultures were treated with 20&#160;&#956;M A&#946;<sub>25&#8211;35</sub> for 24 h as described in &#8220;<xref rid="Sec2" ref-type="sec">Materials and Methods</xref>&#8221;. <bold>a</bold> Total mRNA was isolated and APP mRNA expression in primary cultures was monitored in response to A&#946; exposure. <bold>b</bold> Intracellular holoAPP (<italic>hAPP</italic>) protein detection was carried out using an antibody to the APP C terminus. <bold>c</bold> Tubulin was used as a control. <italic>C</italic> control, <italic>A&#946;</italic> A&#946; treatment for 24&#160;h. **<italic>P</italic>&#8201;&lt;&#8201;0.01, significantly different from control using Dunnett post hoc test</p></caption>
###xml 1704 1704 1664 1664 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="12031_2009_9192_Fig1_HTML" id="MO1"/>
###xml 1141 1704 1117 1664 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Figure&#160;1</label><caption><p textid="23">A&#946; decreases <italic>APP</italic> expression in primary neuronal cultures. Primary cortical neuronal cultures were treated with 20&#160;&#956;M A&#946;<sub>25&#8211;35</sub> for 24 h as described in &#8220;<xref rid="Sec2" ref-type="sec">Materials and Methods</xref>&#8221;. <bold>a</bold> Total mRNA was isolated and APP mRNA expression in primary cultures was monitored in response to A&#946; exposure. <bold>b</bold> Intracellular holoAPP (<italic>hAPP</italic>) protein detection was carried out using an antibody to the APP C terminus. <bold>c</bold> Tubulin was used as a control. <italic>C</italic> control, <italic>A&#946;</italic> A&#946; treatment for 24&#160;h. **<italic>P</italic>&#8201;&lt;&#8201;0.01, significantly different from control using Dunnett post hoc test</p></caption><graphic position="anchor" xlink:href="12031_2009_9192_Fig1_HTML" id="MO1"/></fig>
###xml 1704 1712 1664 1672 <label xmlns:xlink="http://www.w3.org/1999/xlink">Figure&#160;2</label>
###xml 1876 1877 1830 1831 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1912 1916 1866 1870 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hAPP</italic>
###xml 1948 1953 1902 1907 <italic xmlns:xlink="http://www.w3.org/1999/xlink">esAPP</italic>
###xml 1980 1985 1934 1939 <italic xmlns:xlink="http://www.w3.org/1999/xlink">isAPP</italic>
###xml 2087 2088 2041 2042 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 2115 2123 2069 2077 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APP CTFs</italic>
###xml 2172 2173 2126 2127 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 2205 2206 2159 2160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 2220 2221 2174 2175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 2369 2370 2321 2322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 2380 2385 2332 2334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A&#946;</italic>
###xml 1712 2410 1672 2356 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="24">Effect of A&#946; on CTF production. Following incubation of hippocampal neurons with A&#946; peptide, cell lysates and conditioned medium were collected and analyzed. <bold>a</bold> Endogenous intracellular holoAPP (<italic>hAPP</italic>), extracellular secreted sAPP (<italic>esAPP</italic>), and intracellular sAPP (<italic>isAPP</italic>). APP and sAPP were distinguished using the APP C-terminal antibody and the APP N-terminal antibody. <bold>b</bold> APP C-terminal fragments (<italic>APP CTFs</italic>) were detected with an APP C-terminal antibody. <bold>c</bold> Total GSK3 expression levels. *<italic>P</italic>&#8201;&lt;&#8201;0.05 and **<italic>P</italic>&#8201;&lt;&#8201;0.01, significantly different from control using Dunnett post hoc test. Values are expressed as mean&#8201;&#177;&#8201;SEM from three independent experiments. <italic>C</italic> control, <italic>A&#946;</italic> A&#946; treatment for 24&#160;h</p>
###xml 1712 2410 1672 2356 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="24">Effect of A&#946; on CTF production. Following incubation of hippocampal neurons with A&#946; peptide, cell lysates and conditioned medium were collected and analyzed. <bold>a</bold> Endogenous intracellular holoAPP (<italic>hAPP</italic>), extracellular secreted sAPP (<italic>esAPP</italic>), and intracellular sAPP (<italic>isAPP</italic>). APP and sAPP were distinguished using the APP C-terminal antibody and the APP N-terminal antibody. <bold>b</bold> APP C-terminal fragments (<italic>APP CTFs</italic>) were detected with an APP C-terminal antibody. <bold>c</bold> Total GSK3 expression levels. *<italic>P</italic>&#8201;&lt;&#8201;0.05 and **<italic>P</italic>&#8201;&lt;&#8201;0.01, significantly different from control using Dunnett post hoc test. Values are expressed as mean&#8201;&#177;&#8201;SEM from three independent experiments. <italic>C</italic> control, <italic>A&#946;</italic> A&#946; treatment for 24&#160;h</p></caption>
###xml 2410 2410 2356 2356 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="12031_2009_9192_Fig2_HTML" id="MO2"/>
###xml 1704 2410 1664 2356 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig2"><label>Figure&#160;2</label><caption><p textid="24">Effect of A&#946; on CTF production. Following incubation of hippocampal neurons with A&#946; peptide, cell lysates and conditioned medium were collected and analyzed. <bold>a</bold> Endogenous intracellular holoAPP (<italic>hAPP</italic>), extracellular secreted sAPP (<italic>esAPP</italic>), and intracellular sAPP (<italic>isAPP</italic>). APP and sAPP were distinguished using the APP C-terminal antibody and the APP N-terminal antibody. <bold>b</bold> APP C-terminal fragments (<italic>APP CTFs</italic>) were detected with an APP C-terminal antibody. <bold>c</bold> Total GSK3 expression levels. *<italic>P</italic>&#8201;&lt;&#8201;0.05 and **<italic>P</italic>&#8201;&lt;&#8201;0.01, significantly different from control using Dunnett post hoc test. Values are expressed as mean&#8201;&#177;&#8201;SEM from three independent experiments. <italic>C</italic> control, <italic>A&#946;</italic> A&#946; treatment for 24&#160;h</p></caption><graphic position="anchor" xlink:href="12031_2009_9192_Fig2_HTML" id="MO2"/></fig>
Abeta effects on APP metabolism are unclear, with some reports suggesting that Abeta may be affecting APP transcription, while others suggest it to have an effect at the APP processing/catabolic levels (Davis-Salinas et al. 1995; Schmitt et al. 1997; Carlson et al. 2000). In our work, primary neuronal cultures were incubated with and without Abeta25-35 during 24 h and total RNA extracted for Northern blot analysis (Fig. 1a). Although Abeta induction of APP transcription was previously reported in a neuronal hybrid cell line and in cultured astrocytes (Le et al. 1995; Moreno-Flores et al. 1998), under our experimental conditions, Abeta treatment lead to a clear decrease in APP expression in primary cortical cultures. Accordingly, APP intracellular protein levels also dropped a concordant 0.4-fold below control levels upon Abeta exposure (Fig. 1b). Similar results were obtained for hippocampal cultures, with Abeta leading to a decrease in APP intracellular levels (as detected using an APP C-terminal antibody, Fig. 2a), again supporting a role for Abeta in modulating APP transcriptional levels in primary hippocampal cultures. Figure 1Abeta decreases APP expression in primary neuronal cultures. Primary cortical neuronal cultures were treated with 20 muM Abeta25-35 for 24 h as described in "Materials and Methods". a Total mRNA was isolated and APP mRNA expression in primary cultures was monitored in response to Abeta exposure. b Intracellular holoAPP (hAPP) protein detection was carried out using an antibody to the APP C terminus. c Tubulin was used as a control. C control, Abeta Abeta treatment for 24 h. **P < 0.01, significantly different from control using Dunnett post hoc testFigure 2Effect of Abeta on CTF production. Following incubation of hippocampal neurons with Abeta peptide, cell lysates and conditioned medium were collected and analyzed. a Endogenous intracellular holoAPP (hAPP), extracellular secreted sAPP (esAPP), and intracellular sAPP (isAPP). APP and sAPP were distinguished using the APP C-terminal antibody and the APP N-terminal antibody. b APP C-terminal fragments (APP CTFs) were detected with an APP C-terminal antibody. c Total GSK3 expression levels. *P < 0.05 and **P < 0.01, significantly different from control using Dunnett post hoc test. Values are expressed as mean +/- SEM from three independent experiments. C control, Abeta Abeta treatment for 24 h
###end p 22
###begin p 23
###xml 16 19 13 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APP</italic>
###xml 126 131 119 124 <sub xmlns:xlink="http://www.w3.org/1999/xlink">25&#8211;35</sub>
###xml 158 179 151 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Sec2" ref-type="sec">Materials and Methods</xref>
###xml 182 183 175 176 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 297 298 287 288 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 322 326 312 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hAPP</italic>
###xml 403 404 393 394 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 436 437 426 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 447 452 437 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A&#946;</italic>
###xml 481 482 465 466 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Abeta decreases APP expression in primary neuronal cultures. Primary cortical neuronal cultures were treated with 20 muM Abeta25-35 for 24 h as described in "Materials and Methods". a Total mRNA was isolated and APP mRNA expression in primary cultures was monitored in response to Abeta exposure. b Intracellular holoAPP (hAPP) protein detection was carried out using an antibody to the APP C terminus. c Tubulin was used as a control. C control, Abeta Abeta treatment for 24 h. **P < 0.01, significantly different from control using Dunnett post hoc test
###end p 23
###begin p 24
###xml 164 165 158 159 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 200 204 194 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hAPP</italic>
###xml 236 241 230 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">esAPP</italic>
###xml 268 273 262 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink">isAPP</italic>
###xml 375 376 369 370 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 403 411 397 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APP CTFs</italic>
###xml 460 461 454 455 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 493 494 487 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 508 509 502 503 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 657 658 649 650 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 668 673 660 662 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A&#946;</italic>
Effect of Abeta on CTF production. Following incubation of hippocampal neurons with Abeta peptide, cell lysates and conditioned medium were collected and analyzed. a Endogenous intracellular holoAPP (hAPP), extracellular secreted sAPP (esAPP), and intracellular sAPP (isAPP). APP and sAPP were distinguished using the APP C-terminal antibody and the APP N-terminal antibody. b APP C-terminal fragments (APP CTFs) were detected with an APP C-terminal antibody. c Total GSK3 expression levels. *P < 0.05 and **P < 0.01, significantly different from control using Dunnett post hoc test. Values are expressed as mean +/- SEM from three independent experiments. C control, Abeta Abeta treatment for 24 h
###end p 24
###begin title 25
Abeta Induces Accumulation of APP C-Terminal Fragments
###end title 25
###begin p 26
###xml 24 29 21 26 <sub xmlns:xlink="http://www.w3.org/1999/xlink">25&#8211;35</sub>
###xml 87 88 84 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 294 295 291 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 411 412 408 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 513 517 510 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">2009</xref>
###xml 551 555 545 549 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1&#8211;42</sub>
###xml 649 653 640 644 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1&#8211;40</sub>
###xml 678 682 669 673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">2000</xref>
###xml 883 884 871 872 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 1095 1096 1080 1081 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 1493 1497 1456 1460 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1&#8211;42</sub>
###xml 1547 1551 1510 1514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR40">1995</xref>
###xml 1725 1729 1684 1688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">2006</xref>
###xml 1779 1780 1738 1739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 2037 2041 1996 2000 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">2009</xref>
Our data show that Abeta25-35 provokes a decrease in intracellular holoAPP (hAPP, Fig. 2a), detected using the APP C-terminal antibody in primary neuronal cultures. Concomitantly, using the APP N-terminal antibody 22C11, we could observe a decrease in extracellular sAPP secretion (esAPP, Fig. 2a) and an increase in APP intracellular levels. The latter represents intracellularly accumulated sAPP (isAPP, Fig. 2a) since hAPP levels decreased. This isAPP retention was previously reported by us (Henriques et al. 2009) in various cell types, and Abeta1-42 elicits a similar response. Retention of isAPP was also observed with the physiological Abeta1-40 peptide (Carlson et al. 2000). In this case, increases in medium secreted proteins, such as IL-8, concomitant with decreases in sAPP secretion, by 10-30%, were reported. Given that Abeta was clearly altering APP processing (Fig. 2), we monitored the levels of other APP proteolytic fragments and observed that these too were affected. The levels of endogenous CTFs produced by APP proteolytic processing increased with Abeta treatment (Fig. 2b). This suggests that gamma-secretase activity was inhibited by Abeta and/or that CTFs were not accessible for gamma-secretase cleavage. However, direct measurement of gamma-secretase activity did not yield any significant alteration (data not shown), suggesting that CTF cleavage by gamma-secretase activity per se was not hindered. An accumulation of amyloidogenic APP CTFs in response to Abeta1-42 exposure was previously observed by Yang et al. (1995) in APP transfected HEK293 cells. In neuronally derived cells, gamma-secretase cleavage was described to occur at the plasma membrane and/or early endosomes (Kaether et al. 2006). Thus, the neuronal CTF increase observed (Fig. 2b) probably reflects a block in the transport to plasma membrane and a subsequent decrease in proteolytic cleavage of CTFs. This correlates well with our findings of isAPP retention within cytoskeleton-associated vesicular-like structures (Henriques et al. 2009). Hence, increased accumulation of CTFs also correlates with decreased AICD production.
###end p 26
###begin p 27
###xml 130 134 130 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">2001</xref>
###xml 242 245 242 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APP</italic>
###xml 257 265 257 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSK3&#946;</italic>
###xml 278 282 275 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">2003</xref>
###xml 300 304 297 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR36">2004</xref>
###xml 325 329 322 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">2005</xref>
###xml 532 533 529 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 590 591 587 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
AICD has been described as an APP nuclear signal peptide that can form a transcriptional active complex with Fe65 (Cao and Sudhof 2001). AICD-containing complexes were reported to induce transcriptional activation of several genes, including APP itself and GSK3beta (Kim et al. 2003; von Rotz et al. 2004; Ryan and Pimplikar 2005). Thus, increased CTFs and concomitant decreased AICD levels would predict decreases in the AICD nuclear pool and signaling. This is consistent with the observed decrease in APP expression levels (Fig. 1a) and a significant decrease in total GSK3 levels (Fig. 2c). Direct measurements of AICD were not possible given that the endogenous levels in primary cultures are difficult to detect.
###end p 27
###begin title 28
Abeta Decreases Nuclear Targeting of APP C-Terminal Proteolytic Products and Fe65
###end title 28
###begin p 29
###xml 66 69 63 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APP</italic>
###xml 131 132 128 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 137 138 134 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 441 442 435 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 708 709 702 703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 855 856 846 847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 931 932 922 923 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 1192 1193 1180 1181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 1470 1478 1455 1463 <label xmlns:xlink="http://www.w3.org/1999/xlink">Figure&#160;3</label>
###xml 1595 1600 1574 1579 <sub xmlns:xlink="http://www.w3.org/1999/xlink">25&#8211;35</sub>
###xml 1795 1807 1771 1783 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red staining</italic>
###xml 1843 1857 1819 1833 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green staining</italic>
###xml 1972 1973 1948 1949 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 2042 2043 2018 2019 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 2134 2145 2110 2121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">white lines</italic>
###xml 2185 2186 2161 2162 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 2188 2189 2164 2165 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 2334 2346 2310 2322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red staining</italic>
###xml 2428 2442 2404 2418 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green staining</italic>
###xml 2445 2446 2421 2422 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 2456 2461 2432 2434 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A&#946;</italic>
###xml 1478 2486 1463 2456 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="30">A&#946; induces alterations in AICD and Fe65 nuclear targeting. Hippocampal neuronal cultures were incubated with A&#946;<sub>25&#8211;35</sub> for 24&#160;h and subsequently fixed with paraformaldehyde. Immunofluorescence analyses were carried out using anti-&#946;-APP C-terminal and anti-Fe65 antibodies, labeled with a Texas Red-conjugated (<italic>red staining</italic>) or with a fluorescein-conjugated (<italic>green staining</italic>) antibody, respectively. Cells were mounted with an antifading reagent containing DAPI for nuclei acids staining. <bold>a</bold> AICD and Fe65 immunoreactivity was analyzed by confocal microscopy. <bold>b</bold> Representative profiles. Fluorescence intensity profiles represent the voxels through the <italic>white lines</italic> indicated in the merged image shown in <bold>a</bold>. <bold>c</bold> The identity of AICD fragments at the nucleus was shown by the positive immunoreactivity for the APP C-terminal antibody (Texas Red-conjugated, <italic>red staining</italic>) and the negative immunoreactivity for the 4G8 antibody (fluorescein-conjugated, <italic>green staining</italic>). <italic>C</italic> control, <italic>A&#946;</italic> A&#946; treatment for 24&#160;h</p>
###xml 1478 2486 1463 2456 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="30">A&#946; induces alterations in AICD and Fe65 nuclear targeting. Hippocampal neuronal cultures were incubated with A&#946;<sub>25&#8211;35</sub> for 24&#160;h and subsequently fixed with paraformaldehyde. Immunofluorescence analyses were carried out using anti-&#946;-APP C-terminal and anti-Fe65 antibodies, labeled with a Texas Red-conjugated (<italic>red staining</italic>) or with a fluorescein-conjugated (<italic>green staining</italic>) antibody, respectively. Cells were mounted with an antifading reagent containing DAPI for nuclei acids staining. <bold>a</bold> AICD and Fe65 immunoreactivity was analyzed by confocal microscopy. <bold>b</bold> Representative profiles. Fluorescence intensity profiles represent the voxels through the <italic>white lines</italic> indicated in the merged image shown in <bold>a</bold>. <bold>c</bold> The identity of AICD fragments at the nucleus was shown by the positive immunoreactivity for the APP C-terminal antibody (Texas Red-conjugated, <italic>red staining</italic>) and the negative immunoreactivity for the 4G8 antibody (fluorescein-conjugated, <italic>green staining</italic>). <italic>C</italic> control, <italic>A&#946;</italic> A&#946; treatment for 24&#160;h</p></caption>
###xml 2486 2486 2456 2456 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="12031_2009_9192_Fig3_HTML" id="MO3"/>
###xml 1470 2486 1455 2456 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig3"><label>Figure&#160;3</label><caption><p textid="30">A&#946; induces alterations in AICD and Fe65 nuclear targeting. Hippocampal neuronal cultures were incubated with A&#946;<sub>25&#8211;35</sub> for 24&#160;h and subsequently fixed with paraformaldehyde. Immunofluorescence analyses were carried out using anti-&#946;-APP C-terminal and anti-Fe65 antibodies, labeled with a Texas Red-conjugated (<italic>red staining</italic>) or with a fluorescein-conjugated (<italic>green staining</italic>) antibody, respectively. Cells were mounted with an antifading reagent containing DAPI for nuclei acids staining. <bold>a</bold> AICD and Fe65 immunoreactivity was analyzed by confocal microscopy. <bold>b</bold> Representative profiles. Fluorescence intensity profiles represent the voxels through the <italic>white lines</italic> indicated in the merged image shown in <bold>a</bold>. <bold>c</bold> The identity of AICD fragments at the nucleus was shown by the positive immunoreactivity for the APP C-terminal antibody (Texas Red-conjugated, <italic>red staining</italic>) and the negative immunoreactivity for the 4G8 antibody (fluorescein-conjugated, <italic>green staining</italic>). <italic>C</italic> control, <italic>A&#946;</italic> A&#946; treatment for 24&#160;h</p></caption><graphic position="anchor" xlink:href="12031_2009_9192_Fig3_HTML" id="MO3"/></fig>
Our observation that Abeta increased APP CTF levels and decreased APP transcriptional activation and GSK3 expression levels (Figs. 1 and 2) is consistent with a decrease in AICD production and subsequent decreased transactivation of AICD downstream genes. Hence, we focused on AICD/Fe65 nuclear targeting and complex formation. The nuclear targeting of APP C-terminal proteolytic products was clearly hindered in the presence of Abeta (Fig. 3a, Texas Red staining). The APP C-terminal peptides detected in the nucleus and positive for the APP C-terminal antibody were negative for the 4G8 antibody, reinforcing the identity of the nuclear targeted APP C-terminal peptides as AICD proteolytic fragments (Fig. 3c). Under our experimental conditions, Abeta exposure decreased not only the intensity of nuclear APP C-terminal punctuate immunoreactivity (Fig. 3a, Texas Red staining) but also Fe65 nuclear intensity and targeting (Fig. 3a, green fluorescein staining). As a consequence, the co-localization of nuclear AICD-Fe65 was also compromised. Confocal profiling demonstrated that both proteins dramatically decreased in the nucleus (DAPI-positive organelle) following Abeta treatment (Fig. 3b). Hence, the blue trace (denotes the nucleus) is sustained with Abeta exposure, whereas the red and green traces for AICD and Fe65, respectively, drop similarly. Of note, this analysis was carried out in non-apoptotic cells, as denoted by nucleus morphology (DAPI staining). Figure 3Abeta induces alterations in AICD and Fe65 nuclear targeting. Hippocampal neuronal cultures were incubated with Abeta25-35 for 24 h and subsequently fixed with paraformaldehyde. Immunofluorescence analyses were carried out using anti-beta-APP C-terminal and anti-Fe65 antibodies, labeled with a Texas Red-conjugated (red staining) or with a fluorescein-conjugated (green staining) antibody, respectively. Cells were mounted with an antifading reagent containing DAPI for nuclei acids staining. a AICD and Fe65 immunoreactivity was analyzed by confocal microscopy. b Representative profiles. Fluorescence intensity profiles represent the voxels through the white lines indicated in the merged image shown in a. c The identity of AICD fragments at the nucleus was shown by the positive immunoreactivity for the APP C-terminal antibody (Texas Red-conjugated, red staining) and the negative immunoreactivity for the 4G8 antibody (fluorescein-conjugated, green staining). C control, Abeta Abeta treatment for 24 h
###end p 29
###begin p 30
###xml 117 122 111 116 <sub xmlns:xlink="http://www.w3.org/1999/xlink">25&#8211;35</sub>
###xml 317 329 308 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red staining</italic>
###xml 365 379 356 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green staining</italic>
###xml 494 495 485 486 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 564 565 555 556 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 656 667 647 658 <italic xmlns:xlink="http://www.w3.org/1999/xlink">white lines</italic>
###xml 707 708 698 699 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 710 711 701 702 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 856 868 847 859 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red staining</italic>
###xml 950 964 941 955 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green staining</italic>
###xml 967 968 958 959 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 978 983 969 971 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A&#946;</italic>
Abeta induces alterations in AICD and Fe65 nuclear targeting. Hippocampal neuronal cultures were incubated with Abeta25-35 for 24 h and subsequently fixed with paraformaldehyde. Immunofluorescence analyses were carried out using anti-beta-APP C-terminal and anti-Fe65 antibodies, labeled with a Texas Red-conjugated (red staining) or with a fluorescein-conjugated (green staining) antibody, respectively. Cells were mounted with an antifading reagent containing DAPI for nuclei acids staining. a AICD and Fe65 immunoreactivity was analyzed by confocal microscopy. b Representative profiles. Fluorescence intensity profiles represent the voxels through the white lines indicated in the merged image shown in a. c The identity of AICD fragments at the nucleus was shown by the positive immunoreactivity for the APP C-terminal antibody (Texas Red-conjugated, red staining) and the negative immunoreactivity for the 4G8 antibody (fluorescein-conjugated, green staining). C control, Abeta Abeta treatment for 24 h
###end p 30
###begin p 31
###xml 135 136 135 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 963 964 957 958 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 1119 1126 1110 1117 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1</label>
###xml 1126 1198 1117 1186 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="32">AICD and Fe65 nuclear targeting and co-localization in response to A&#946;</p>
###xml 1126 1198 1117 1186 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="32">AICD and Fe65 nuclear targeting and co-localization in response to A&#946;</p></caption>
###xml 1198 1199 1186 1187 <th xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">&#160;</th>
###xml 1199 1243 1187 1231 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="3">Nuclear targeting as a % of total population</th>
###xml 1243 1304 1231 1292 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="3">% of each protein co-localizing to the complex in the nucleus</th>
###xml 1198 1304 1186 1292 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th rowspan="2">&#160;</th><th colspan="3">Nuclear targeting as a % of total population</th><th colspan="3">% of each protein co-localizing to the complex in the nucleus</th></tr>
###xml 1304 1305 1292 1293 <th xmlns:xlink="http://www.w3.org/1999/xlink">C</th>
###xml 1305 1310 1293 1295 <th xmlns:xlink="http://www.w3.org/1999/xlink">A&#946;</th>
###xml 1310 1323 1295 1305 <th xmlns:xlink="http://www.w3.org/1999/xlink">% Dec + A&#946;</th>
###xml 1323 1324 1305 1306 <th xmlns:xlink="http://www.w3.org/1999/xlink">C</th>
###xml 1324 1329 1306 1308 <th xmlns:xlink="http://www.w3.org/1999/xlink">A&#946;</th>
###xml 1329 1342 1308 1318 <th xmlns:xlink="http://www.w3.org/1999/xlink">% Dec + A&#946;</th>
###xml 1304 1342 1292 1318 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>C</th><th>A&#946;</th><th>% Dec + A&#946;</th><th>C</th><th>A&#946;</th><th>% Dec + A&#946;</th></tr>
###xml 1198 1342 1186 1318 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th rowspan="2">&#160;</th><th colspan="3">Nuclear targeting as a % of total population</th><th colspan="3">% of each protein co-localizing to the complex in the nucleus</th></tr><tr><th>C</th><th>A&#946;</th><th>% Dec + A&#946;</th><th>C</th><th>A&#946;</th><th>% Dec + A&#946;</th></tr></thead>
###xml 1342 1346 1318 1322 <td xmlns:xlink="http://www.w3.org/1999/xlink">AICD</td>
###xml 1346 1356 1322 1330 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">46&#8201;&#177;&#8201;3.0</td>
###xml 1356 1366 1330 1338 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">27&#8201;&#177;&#8201;1.7</td>
###xml 1366 1368 1338 1340 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">42</td>
###xml 1368 1378 1340 1348 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">33&#8201;&#177;&#8201;2.0</td>
###xml 1378 1388 1348 1356 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">21&#8201;&#177;&#8201;1.9</td>
###xml 1388 1390 1356 1358 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">36</td>
###xml 1342 1390 1318 1358 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>AICD</td><td char="&#177;" align="char">46&#8201;&#177;&#8201;3.0</td><td char="&#177;" align="char">27&#8201;&#177;&#8201;1.7</td><td char="." align="char">42</td><td char="&#177;" align="char">33&#8201;&#177;&#8201;2.0</td><td char="&#177;" align="char">21&#8201;&#177;&#8201;1.9</td><td char="." align="char">36</td></tr>
###xml 1390 1394 1358 1362 <td xmlns:xlink="http://www.w3.org/1999/xlink">Fe65</td>
###xml 1394 1404 1362 1370 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">36&#8201;&#177;&#8201;2.0</td>
###xml 1404 1414 1370 1378 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">16&#8201;&#177;&#8201;1.4</td>
###xml 1414 1416 1378 1380 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">56</td>
###xml 1416 1426 1380 1388 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">22&#8201;&#177;&#8201;1.1</td>
###xml 1426 1436 1388 1396 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">20&#8201;&#177;&#8201;1.6</td>
###xml 1436 1438 1396 1398 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">10</td>
###xml 1390 1438 1358 1398 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Fe65</td><td char="&#177;" align="char">36&#8201;&#177;&#8201;2.0</td><td char="&#177;" align="char">16&#8201;&#177;&#8201;1.4</td><td char="." align="char">56</td><td char="&#177;" align="char">22&#8201;&#177;&#8201;1.1</td><td char="&#177;" align="char">20&#8201;&#177;&#8201;1.6</td><td char="." align="char">10</td></tr>
###xml 1342 1438 1318 1398 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td>AICD</td><td char="&#177;" align="char">46&#8201;&#177;&#8201;3.0</td><td char="&#177;" align="char">27&#8201;&#177;&#8201;1.7</td><td char="." align="char">42</td><td char="&#177;" align="char">33&#8201;&#177;&#8201;2.0</td><td char="&#177;" align="char">21&#8201;&#177;&#8201;1.9</td><td char="." align="char">36</td></tr><tr><td>Fe65</td><td char="&#177;" align="char">36&#8201;&#177;&#8201;2.0</td><td char="&#177;" align="char">16&#8201;&#177;&#8201;1.4</td><td char="." align="char">56</td><td char="&#177;" align="char">22&#8201;&#177;&#8201;1.1</td><td char="&#177;" align="char">20&#8201;&#177;&#8201;1.6</td><td char="." align="char">10</td></tr></tbody>
###xml 1198 1438 1186 1398 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th rowspan="2">&#160;</th><th colspan="3">Nuclear targeting as a % of total population</th><th colspan="3">% of each protein co-localizing to the complex in the nucleus</th></tr><tr><th>C</th><th>A&#946;</th><th>% Dec + A&#946;</th><th>C</th><th>A&#946;</th><th>% Dec + A&#946;</th></tr></thead><tbody><tr><td>AICD</td><td char="&#177;" align="char">46&#8201;&#177;&#8201;3.0</td><td char="&#177;" align="char">27&#8201;&#177;&#8201;1.7</td><td char="." align="char">42</td><td char="&#177;" align="char">33&#8201;&#177;&#8201;2.0</td><td char="&#177;" align="char">21&#8201;&#177;&#8201;1.9</td><td char="." align="char">36</td></tr><tr><td>Fe65</td><td char="&#177;" align="char">36&#8201;&#177;&#8201;2.0</td><td char="&#177;" align="char">16&#8201;&#177;&#8201;1.4</td><td char="." align="char">56</td><td char="&#177;" align="char">22&#8201;&#177;&#8201;1.1</td><td char="&#177;" align="char">20&#8201;&#177;&#8201;1.6</td><td char="." align="char">10</td></tr></tbody></table>
###xml 1438 2058 1398 2010 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="33">Analysis was carried out using a Zeiss confocal microscope co-localization software. The percentage of nuclear AICD and Fe65 immunopositive pixels were determined relative to the total neuronal cell populations, excluding dendrites and axons (nuclear targeting as a percentage of the total population). The &#8220;% of each protein co-localizing to the complex in the nucleus&#8221; represents the percentage of each protein (AICD or Fe65) co-localizing to the other and relative to its total nuclear population. &#8220;% Dec + A&#946;&#8221; is the percentage decrease upon A&#946; addition. Data are presented as mean&#8201;&#177;&#8201;SEM of 40 analyzed cells</p>
###xml 1438 2058 1398 2010 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="33">Analysis was carried out using a Zeiss confocal microscope co-localization software. The percentage of nuclear AICD and Fe65 immunopositive pixels were determined relative to the total neuronal cell populations, excluding dendrites and axons (nuclear targeting as a percentage of the total population). The &#8220;% of each protein co-localizing to the complex in the nucleus&#8221; represents the percentage of each protein (AICD or Fe65) co-localizing to the other and relative to its total nuclear population. &#8220;% Dec + A&#946;&#8221; is the percentage decrease upon A&#946; addition. Data are presented as mean&#8201;&#177;&#8201;SEM of 40 analyzed cells</p></table-wrap-foot>
###xml 1119 2058 1110 2010 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1</label><caption><p textid="32">AICD and Fe65 nuclear targeting and co-localization in response to A&#946;</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">&#160;</th><th colspan="3">Nuclear targeting as a % of total population</th><th colspan="3">% of each protein co-localizing to the complex in the nucleus</th></tr><tr><th>C</th><th>A&#946;</th><th>% Dec + A&#946;</th><th>C</th><th>A&#946;</th><th>% Dec + A&#946;</th></tr></thead><tbody><tr><td>AICD</td><td char="&#177;" align="char">46&#8201;&#177;&#8201;3.0</td><td char="&#177;" align="char">27&#8201;&#177;&#8201;1.7</td><td char="." align="char">42</td><td char="&#177;" align="char">33&#8201;&#177;&#8201;2.0</td><td char="&#177;" align="char">21&#8201;&#177;&#8201;1.9</td><td char="." align="char">36</td></tr><tr><td>Fe65</td><td char="&#177;" align="char">36&#8201;&#177;&#8201;2.0</td><td char="&#177;" align="char">16&#8201;&#177;&#8201;1.4</td><td char="." align="char">56</td><td char="&#177;" align="char">22&#8201;&#177;&#8201;1.1</td><td char="&#177;" align="char">20&#8201;&#177;&#8201;1.6</td><td char="." align="char">10</td></tr></tbody></table><table-wrap-foot><p textid="33">Analysis was carried out using a Zeiss confocal microscope co-localization software. The percentage of nuclear AICD and Fe65 immunopositive pixels were determined relative to the total neuronal cell populations, excluding dendrites and axons (nuclear targeting as a percentage of the total population). The &#8220;% of each protein co-localizing to the complex in the nucleus&#8221; represents the percentage of each protein (AICD or Fe65) co-localizing to the other and relative to its total nuclear population. &#8220;% Dec + A&#946;&#8221; is the percentage decrease upon A&#946; addition. Data are presented as mean&#8201;&#177;&#8201;SEM of 40 analyzed cells</p></table-wrap-foot></table-wrap>
Detailed co-localization studies of AICD and Fe65 immunoreactivity in the nucleus using Zeiss confocal co-localization software (Table 1) also confirmed Abeta-induced alterations in the nuclear targeting of both proteins. The percentage of both AICD and Fe65 positive pixels present in the nucleus, relative to the total neuronal soma population, showed a decrease of 42% and 56%, respectively. Focusing on the nuclear population alone, we were able to determine that the AICD nuclear population co-localizing with Fe65 dropped from 33% to 21% upon addition of Abeta, which represents a 36% decrease. There was no significant difference in the percentage of the Fe65 nuclear population that co-localized with AICD (22% and 20%). Additionally we determined that the AICD population, as a percentage of the total APP C-terminal immunoreactivity, co-localizing to Fe65 in the nucleus decreased from ~15% (33% of the 46% of the nuclear targeted population, see Table 1) to ~5% (21% of 27%) upon exposure to Abeta. Likewise, we determined the values for Fe65, and the decrease was from ~7% (22% of 36%) to ~4% (20% of 16%). Table 1AICD and Fe65 nuclear targeting and co-localization in response to Abeta Nuclear targeting as a % of total population% of each protein co-localizing to the complex in the nucleusCAbeta% Dec + AbetaCAbeta% Dec + AbetaAICD46 +/- 3.027 +/- 1.74233 +/- 2.021 +/- 1.936Fe6536 +/- 2.016 +/- 1.45622 +/- 1.120 +/- 1.610Analysis was carried out using a Zeiss confocal microscope co-localization software. The percentage of nuclear AICD and Fe65 immunopositive pixels were determined relative to the total neuronal cell populations, excluding dendrites and axons (nuclear targeting as a percentage of the total population). The "% of each protein co-localizing to the complex in the nucleus" represents the percentage of each protein (AICD or Fe65) co-localizing to the other and relative to its total nuclear population. "% Dec + Abeta" is the percentage decrease upon Abeta addition. Data are presented as mean +/- SEM of 40 analyzed cells
###end p 31
###begin p 32
AICD and Fe65 nuclear targeting and co-localization in response to Abeta
###end p 32
###begin p 33
Analysis was carried out using a Zeiss confocal microscope co-localization software. The percentage of nuclear AICD and Fe65 immunopositive pixels were determined relative to the total neuronal cell populations, excluding dendrites and axons (nuclear targeting as a percentage of the total population). The "% of each protein co-localizing to the complex in the nucleus" represents the percentage of each protein (AICD or Fe65) co-localizing to the other and relative to its total nuclear population. "% Dec + Abeta" is the percentage decrease upon Abeta addition. Data are presented as mean +/- SEM of 40 analyzed cells
###end p 33
###begin p 34
###xml 236 237 233 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 451 452 448 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 456 464 453 461 <label xmlns:xlink="http://www.w3.org/1999/xlink">Figure&#160;4</label>
###xml 554 555 548 549 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 581 582 575 576 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 716 717 710 711 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 792 793 786 787 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 803 808 797 799 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A&#946;</italic>
###xml 464 833 461 821 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="35">A&#946; effect on Fe65. Fe65 intracellular levels were evaluated using both immunoblotting (<bold>a</bold>) and immunofluorescence (<bold>b</bold>). Fe65 immunoreactivity was analyzed by confocal microscopy at a focus plane above the nucleus and just below the plasma membrane. **<italic>P</italic>&#8201;&lt;&#8201;0.01, significantly different from control using Dunnett post hoc test. <italic>C</italic> control, <italic>A&#946;</italic> A&#946; treatment for 24&#160;h</p>
###xml 464 833 461 821 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="35">A&#946; effect on Fe65. Fe65 intracellular levels were evaluated using both immunoblotting (<bold>a</bold>) and immunofluorescence (<bold>b</bold>). Fe65 immunoreactivity was analyzed by confocal microscopy at a focus plane above the nucleus and just below the plasma membrane. **<italic>P</italic>&#8201;&lt;&#8201;0.01, significantly different from control using Dunnett post hoc test. <italic>C</italic> control, <italic>A&#946;</italic> A&#946; treatment for 24&#160;h</p></caption>
###xml 833 833 821 821 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="12031_2009_9192_Fig4_HTML" id="MO4"/>
###xml 456 833 453 821 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig4"><label>Figure&#160;4</label><caption><p textid="35">A&#946; effect on Fe65. Fe65 intracellular levels were evaluated using both immunoblotting (<bold>a</bold>) and immunofluorescence (<bold>b</bold>). Fe65 immunoreactivity was analyzed by confocal microscopy at a focus plane above the nucleus and just below the plasma membrane. **<italic>P</italic>&#8201;&lt;&#8201;0.01, significantly different from control using Dunnett post hoc test. <italic>C</italic> control, <italic>A&#946;</italic> A&#946; treatment for 24&#160;h</p></caption><graphic position="anchor" xlink:href="12031_2009_9192_Fig4_HTML" id="MO4"/></fig>
Given that the nuclear abundance of both AICD and Fe65 were affected, we also tested the latter directly by immunoblotting and immunofluorescence. Our data showed a clear decrease in Fe65 intracellular levels in response to Abeta (Fig. 4a). This was also evident by confocal microscopy at a focus plane above the nucleus and just below the plasma membrane where Fe65 immunoreactivity decreased overall, being particularly visible along neurites (Fig. 4b). Figure 4Abeta effect on Fe65. Fe65 intracellular levels were evaluated using both immunoblotting (a) and immunofluorescence (b). Fe65 immunoreactivity was analyzed by confocal microscopy at a focus plane above the nucleus and just below the plasma membrane. **P < 0.01, significantly different from control using Dunnett post hoc test. C control, Abeta Abeta treatment for 24 h
###end p 34
###begin p 35
###xml 90 91 87 88 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 117 118 114 115 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 252 253 249 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 328 329 325 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 339 344 336 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A&#946;</italic>
Abeta effect on Fe65. Fe65 intracellular levels were evaluated using both immunoblotting (a) and immunofluorescence (b). Fe65 immunoreactivity was analyzed by confocal microscopy at a focus plane above the nucleus and just below the plasma membrane. **P < 0.01, significantly different from control using Dunnett post hoc test. C control, Abeta Abeta treatment for 24 h
###end p 35
###begin p 36
Taken together, our results suggest that Abeta is affecting AICD production, its nuclear translocation, and nuclear complex formation with Fe65 whose nuclear targeting is itself decreased. A decrease in AICD production and in the formation of AICD/Fe65 transactivation complexes potentially leads to altered APP nuclear signaling in the presence of Abeta, leading to impaired gene transcriptional activation.
###end p 36
###begin p 37
###xml 51 54 48 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APP</italic>
###xml 715 719 697 701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR33">2002</xref>
In summary, we propose that Abeta leads to reduced APP expression and consequentially diminished Abeta production, which is important for cells exposed to an Abeta-saturated environment. It is attractive to postulate that the aforementioned mechanisms congregate to reduce intracellular accumulation of Abeta and that exogenous Abeta appears to induce a set of concerted cellular responses to prevent its own production, including reduced AICD/Fe65 nuclear targeting. We hypothesize that a physiologically relevant negative feedback mechanism may be operating, tightly coordinating the levels of APP expression and AICD and Abeta production. Further, as APP CTF levels progressively decrease in AD (Sergeant et al. 2002), this feedback mechanism may be lost with the progression of the disease. This would be a physiologically relevant process given that neurons exhibit higher levels of Abeta production. Nonetheless, we cannot exclude that non-physiological Abeta concentrations may trigger neuronal stress mechanisms which may in turn affect APP metabolism and Abeta production; future research will address this question.
###end p 37
###begin p 38
###xml 305 308 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
This study is supported by the European Union VI Framework Program (Project cNeupro), Fundacao para a Ciencia e Tecnologia (FCT) of the Portuguese Ministry of Science and Technology (POCTI/NSE/40682, POCI/BIA-BCM/58469, REEQ/1023/BIO/2005), and Centro de Biologia Celular, Universidade de Aveiro. AGH and SIV were recipients of a Ph.D (BD/16071) and post-doctoral (BPD/19515) fellowships, respectively, from FCT.
###end p 38
###begin title 39
References
###end title 39
###begin article-title 40
ADAMs family members as amyloid precursor protein alpha-secretases
###end article-title 40
###begin article-title 41
Monitoring protein phosphatase 1 isoform levels as a marker for cellular stress
###end article-title 41
###begin article-title 42
Phosphorylation-dependent regulation of the interaction of amyloid precursor protein with Fe65 affects the production of beta-amyloid
###end article-title 42
###begin article-title 43
Exchange of N-CoR corepressor and Tip60 coactivator complexes links gene expression by NF-kappaB and beta-amyloid precursor protein
###end article-title 43
###begin article-title 44
Optimized survival of hippocampal neurons in B27-supplemented Neurobasal, a new serum-free medium combination
###end article-title 44
###begin article-title 45
Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor
###end article-title 45
###begin article-title 46
A transcriptionally [correction of transcriptively] active complex of APP with Fe65 and histone acetyltransferase Tip60
###end article-title 46
###begin article-title 47
Gamma-secretase complex assembly within the early secretory pathway
###end article-title 47
###begin article-title 48
###xml 63 68 <span type="species:ncbi:9606">human</span>
Regulation of amyloid precursor protein processing by Abeta in human glioma cells
###end article-title 48
###begin article-title 49
Signal transduction therapeutics: relevance for Alzheimer's disease
###end article-title 49
###begin article-title 50
Enhanced generation of Alzheimer's Abeta following chronic exposure to phorbol ester correlates with differential effects on alpha and epsilon isozymes of protein kinase C
###end article-title 50
###begin article-title 51
Amyloid beta-protein induces its own production in cultured degenerating cerebrovascular smooth muscle cells
###end article-title 51
###begin article-title 52
Activity-dependent isolation of the presenilin-gamma-secretase complex reveals nicastrin and a gamma substrate
###end article-title 52
###begin article-title 53
Amyloid beta-peptide is produced by cultured cells during normal metabolism
###end article-title 53
###begin article-title 54
Normal cellular processing of the beta-amyloid precursor protein results in the secretion of the amyloid beta peptide and related molecules
###end article-title 54
###begin article-title 55
Isoform specific amyloid-beta protein precursor metabolism
###end article-title 55
###begin article-title 56
Amyloid precursor protein and Notch intracellular domains are generated after transport of their precursors to the cell surface
###end article-title 56
###begin article-title 57
C-terminal fragments of amyloid precursor protein exert neurotoxicity by inducing glycogen synthase kinase-3beta expression
###end article-title 57
###begin article-title 58
The intracellular domain of the beta-amyloid precursor protein is stabilized by Fe65 and translocates to the nucleus in a notch-like manner
###end article-title 58
###begin article-title 59
Beta-amyloid1-40 increases expression of beta-amyloid precursor protein in neuronal hybrid cells
###end article-title 59
###begin article-title 60
Mammalian APH-1 interacts with presenilin and nicastrin and is required for intramembrane proteolysis of amyloid-beta precursor protein and Notch
###end article-title 60
###begin article-title 61
Presenilin 1 is linked with gamma-secretase activity in the detergent solubilized state
###end article-title 61
###begin article-title 62
The beta-amyloid precursor protein functions as a cytosolic anchoring site that prevents Fe65 nuclear translocation
###end article-title 62
###begin article-title 63
BetaA amyloid peptide (25-35) induced APP expression in cultured astrocytes
###end article-title 63
###begin article-title 64
Presenilin-dependent transcriptional control of the Abeta-degrading enzyme neprilysin by intracellular domains of betaAPP and APLP
###end article-title 64
###begin article-title 65
Tyr687 dependent APP endocytosis and Abeta production
###end article-title 65
###begin article-title 66
###xml 52 67 <span type="species:ncbi:10090">transgenic mice</span>
Activation of GSK-3 and phosphorylation of CRMP2 in transgenic mice expressing APP intracellular domain
###end article-title 66
###begin article-title 67
Regulation of beta-amyloid secretion by FE65, an amyloid protein precursor-binding protein
###end article-title 67
###begin article-title 68
Presenilin-dependent gamma-secretase processing of beta-amyloid precursor protein at a site corresponding to the S3 cleavage of Notch
###end article-title 68
###begin article-title 69
###xml 89 94 <span type="species:ncbi:9606">human</span>
Amyloid beta-protein(25-35) increases cellular APP and inhibits the secretion of APPs in human extraneuronal cells
###end article-title 69
###begin article-title 70
Physiological production of the beta-amyloid protein and the mechanism of Alzheimer's disease
###end article-title 70
###begin article-title 71
Progressive decrease of amyloid precursor protein carboxy terminal fragments (APP-CTFs), associated with tau pathology stages, in Alzheimer's disease
###end article-title 71
###begin article-title 72
Beta-amyloid precursor protein cleavage by a membrane-bound protease
###end article-title 72
###begin article-title 73
Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE
###end article-title 73
###begin article-title 74
The APP intracellular domain forms nuclear multiprotein complexes and regulates the transcription of its own precursor
###end article-title 74
###begin article-title 75
Gamma-secretase cleavage and binding to FE65 regulate the nuclear translocation of the intracellular C-terminal domain (ICD) of the APP family of proteins
###end article-title 75
###begin article-title 76
RNA interference silencing of the adaptor molecules ShcC and Fe65 differentially affect amyloid precursor protein processing and Abeta generation
###end article-title 76
###begin article-title 77
The transmembrane domain of the Alzheimer's beta-secretase (BACE1) determines its late Golgi localization and access to beta-amyloid precursor protein (APP) substrate
###end article-title 77
###begin article-title 78
Intracellular A beta 1-42 aggregates stimulate the accumulation of stable, insoluble amyloidogenic fragments of the amyloid precursor protein in transfected cells
###end article-title 78

